The IASLC 18th World Conference on Lung Cancer (WCLC) is planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the International Association for the Study of Lung Cancer (IASLC).
IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. IASLC designates this LIVE CME activity for a maximum of 21 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.
All official Learning Conference Sessions will be accredited except for the Poster Display Sessions, Hands-On Training Sessions, and Industry Supported Symposia.
All individuals able to influence or control content of any CME certified activity that will be presented will be required to complete an electronic Financial Relationships/Conflicts of Interest Disclosure Form prior to the conference. In addition, abstract submitters will have to provide disclosure information for all co-authors at the time of abstract submission.
If individuals refuse to provide this information they will be eliminated from presenting in the conference.
A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used on, patients that benefits the individual in any financial amount, and therefore may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected.
This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.
IASLC CME assures that the planners/reviewers/authors/faculty/peer reviewers et. al. conflicts of interest are identified, reviewed and resolved from all individuals involved in the development or able to influence and control the content of a CME activity. IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners. Any individual who fails or refuses to disclose relevant financial relationships will be disqualified from this CME activity and removed from future IASLC CME activity presentations.
All commercial relationships and conflicts of interest will be identified and thoroughly vetted by the IASLC Ethics Committee, CME Subcommittee, and/or an independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.
All non-FDA approved uses of products must be clearly identified. Disclosures may be made in form of a slide, printed material, or oral statement. Each presenter should reveal his/her disclosure information during his/her presentation, preferably with the visual aid of a slide. Furthermore, commercial employees cannot present abstracts about products of his or her company.
IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
IASLC CME designates this Live Course activity for a maximum of 21 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians will receive credits based on the sessions they attended and were scanned for. Ensure that you get your badge scanned when going into a session.
The IASLC 18th World Conference on Lung Cancer is an educational and scientific event which, due to its multidisciplinary nature, will cover all aspects of the management of lung cancers, mesothelioma, thymic and other thoracic malignancies.
Participants will learn about tobacco control and smoking cessation programs and how to implement them in their daily practice. Participants will update their knowledge on early detection and screening.
The conference will provide lectures on accurate diagnosis, including molecular diagnosis, state-of-the-art treatment of thoracic malignancies, and recent diagnostic and therapeutic advances. Participants will learn about palliative care and its implementation in daily practice.
Participants will be informed about the possibilities for continuous medical education. They will learn about clinical trial designs and how to become successful investigators of co-operative research groups. The conference will also allow participants to be better informed about patient support and advocacy groups.
Overall, the participants of the WCLC will benefit in regard to learning the best clinical practice in the area of lung cancer and other thoracic malignancies.
At the end of the conference attendees will be able to:
- Identify effective global lung cancer prevention strategies.
- Improve their ability to participate in tobacco control and smoking cessation programs.
- Recognize the current approaches and strategies for early detection and screening of lung cancer.
- Demonstrate the best methods to implement multi-disciplinary tumor boards into community practices.
- Examine evidence-based therapeutic regimens for early stage and locally advanced NSCLC.
- Distinguish evidence-based therapeutic regimens for metastatic NSCLC based on biomarker status and patient/tumor characteristics.
- Define best practices regarding the application of targeted therapies for metastatic NSCLC in frontline and then subsequent settings following acquired resistance to the targeted therapy.
- Describe current and emerging immunotherapy strategies in the context of clinical trials findings and patient selection in metastatic NSCLC.
- Integrate clinical data on maintenance therapy in NSCLC to determine which patients would benefit most from a maintenance regimen.
- Review the clinical significance of optimal biopsy, specimen flow and molecular testing for personalized medicine in non-academic settings.
- Illustrate the molecular pathways that hold promise for therapeutic intervention.
- Outline current therapeutic approaches for limited and extensive small cell lung cancer (SCLC).
- Describe current therapeutic approaches for patients with mesothelioma and thymoma.
- Predict optimal and best practice approaches for supportive and palliative care of patients with thoracic cancers.
- Evaluate the support and survivorship resources available for lung cancer patients and their families.
- Illustrate important aspects of clinical trial design and master protocols.
- Explain to more junior investigators and students on research and technology advances, and encourage them to initiate investigations in lung cancer research.
The official language of the IASLC 18th World Conference on Lung Cancer is English.
The information presented at the IASLC 18th World Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
A conference electronic evaluation form will be emailed to learners after the conference. Participants that wish to receive CME credit will have to complete the online evaluation form in order to receive their CME certificate. CME credits will only be provided for the sessions that learners are scanned in for. The CME certificate will be ready for you to print or save upon completion.
This information is used not only to evaluate the present activity, but also to plan for future programs.
Your opinion is very valuable!